All lobbying filings

NOVOZYMES NORTH AMERICA, INC.

NOVOZYMES NORTH AMERICA, INC. filed a Q4 report for NOVOZYMES NORTH AMERICA, INC. on January 20, 2026.

Lobbying for NOVOZYMES NORTH AMERICA, INC.

All filings by NOVOZYMES NORTH AMERICA, INC. · Everything NOVOZYMES NORTH AMERICA, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$150,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

North Carolina

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Environment/Superfund

Issues related to renewables fuels and E-15 - no specific legislation.

Agriculture

Issues related to sustainability - no specific legislation. Issues related to animal feed additives, sustainability, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, and biological product in agriculture - no specific legislation. Issues related to biotechnology and biological products including H.R.2756/S.1387 - National Biotechnology Initiative Act of 2025. Issues related to dietary supplements - no specific legislation.

Transportation

Issues pertaining to Supply Chain including movement of containers - no specific legislation. SHIP It Act (not yet introduced) - issues related to tariffs.

Bills named in this filing 2

H.R. 2756
National Biotechnology Initiative Act of 2025
S. 1387
National Biotechnology Initiative Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.